JP2011525363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525363A5 JP2011525363A5 JP2011515200A JP2011515200A JP2011525363A5 JP 2011525363 A5 JP2011525363 A5 JP 2011525363A5 JP 2011515200 A JP2011515200 A JP 2011515200A JP 2011515200 A JP2011515200 A JP 2011515200A JP 2011525363 A5 JP2011525363 A5 JP 2011525363A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- complex
- vwf
- fviii
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047303 von Willebrand Factor Proteins 0.000 claims 63
- 102100036537 von Willebrand factor Human genes 0.000 claims 63
- 229960001134 von willebrand factor Drugs 0.000 claims 63
- 108010054218 Factor VIII Proteins 0.000 claims 62
- 102000001690 Factor VIII Human genes 0.000 claims 62
- 229960000301 factor viii Drugs 0.000 claims 62
- 229920001184 polypeptide Polymers 0.000 claims 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims 61
- 239000013598 vector Substances 0.000 claims 15
- 238000001727 in vivo Methods 0.000 claims 13
- 238000011084 recovery Methods 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000013612 plasmid Substances 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 2
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08011429.1 | 2008-06-24 | ||
| EP08011429 | 2008-06-24 | ||
| PCT/EP2009/004549 WO2009156137A1 (en) | 2008-06-24 | 2009-06-24 | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525363A JP2011525363A (ja) | 2011-09-22 |
| JP2011525363A5 true JP2011525363A5 (enExample) | 2012-07-26 |
| JP5832285B2 JP5832285B2 (ja) | 2015-12-16 |
Family
ID=40042814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515200A Expired - Fee Related JP5832285B2 (ja) | 2008-06-24 | 2009-06-24 | 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8575104B2 (enExample) |
| EP (2) | EP2865760B1 (enExample) |
| JP (1) | JP5832285B2 (enExample) |
| KR (2) | KR101648734B1 (enExample) |
| CN (2) | CN103739712B (enExample) |
| AU (1) | AU2009262476C1 (enExample) |
| CA (1) | CA2728012C (enExample) |
| DK (2) | DK2865760T3 (enExample) |
| ES (2) | ES2654336T3 (enExample) |
| PL (1) | PL2291523T3 (enExample) |
| RU (1) | RU2528855C2 (enExample) |
| WO (1) | WO2009156137A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| US20110046060A1 (en) | 2009-08-24 | 2011-02-24 | Amunix Operating, Inc., | Coagulation factor IX compositions and methods of making and using same |
| HUE029454T2 (en) * | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| WO2011101242A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| EP2536754A1 (en) * | 2010-02-16 | 2012-12-26 | Novo Nordisk A/S | Factor viii fusion protein |
| JP5826772B2 (ja) * | 2010-02-16 | 2015-12-02 | ノヴォ ノルディスク アー／エス | コンジュゲートタンパク質 |
| US8772462B2 (en) | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| SI2717905T1 (sl) * | 2011-06-10 | 2018-09-28 | Baxalta GmbH | Obravnava bolezni koagulacije z dajanjem rekombinantnega vwf |
| CN111499761A (zh) * | 2012-01-12 | 2020-08-07 | 比奥贝拉蒂治疗公司 | 嵌合因子viii多肽及其用途 |
| KR20140131957A (ko) * | 2012-02-14 | 2014-11-14 | 포톨라 파마슈티컬스, 인코포레이티드 | Xa 인자 억제제에 대한 재조합 해독제를 제조하는 방법 |
| CN111548418A (zh) * | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
| PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| AU2013290173B2 (en) * | 2012-07-11 | 2018-02-15 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| ES2657291T3 (es) * | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| WO2014210546A1 (en) | 2013-06-27 | 2014-12-31 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
| HK1223302A1 (zh) * | 2013-06-28 | 2017-07-28 | Bioverativ Therapeutics Inc. | 具有xten的凝血酶可裂解连接子和其用途 |
| EP3013359A4 (en) * | 2013-06-28 | 2017-01-25 | Biogen MA Inc. | Thrombin cleavable linker |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| ES2693380T3 (es) | 2013-11-08 | 2018-12-11 | Csl Limited | Nuevo método para concentrar el factor de von Willebrand o complejos de este |
| PH12016501323B1 (en) * | 2014-01-10 | 2022-04-29 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| PL3158055T3 (pl) | 2014-06-13 | 2020-03-31 | Csl Limited | Ulepszone wytwarzanie rekombinowanego czynnika von Willebranda w bioreaktorze |
| DE102014011653A1 (de) * | 2014-06-20 | 2015-12-24 | Ulrich Loos | Nachweis von Autoantikörpern gegen den TSH-Rezeptor |
| EP3164150B1 (en) * | 2014-07-02 | 2020-11-04 | CSL Behring Lengnau AG | Modified von willebrand factor |
| US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| AU2016215124B2 (en) * | 2015-02-06 | 2020-08-06 | The University Of North Carolina At Chapel Hill | Optimized human clotting Factor VIII gene expression cassettes and their use |
| KR20170125941A (ko) | 2015-03-06 | 2017-11-15 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자 |
| EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| BR112017023785A2 (pt) | 2015-05-22 | 2018-07-17 | Csl Behring Recombinant Facility Ag | polipeptídeos do fator de von willebrand truncados para tratar hemofilia |
| AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
| WO2017112895A1 (en) * | 2015-12-23 | 2017-06-29 | Haplomics, Inc. | F8 gene repair |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| RU2018128582A (ru) * | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| EP3458085B1 (en) * | 2016-05-20 | 2022-12-07 | Octapharma AG | Glycosylated vwf fusion proteins with improved pharmacokinetics |
| EP3476937A4 (en) * | 2016-06-24 | 2019-12-04 | Mogam Institute for Biomedical Research | CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF |
| US11814421B2 (en) | 2016-11-11 | 2023-11-14 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
| SG11201903954WA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| WO2018234518A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
| FI3648788T5 (fi) | 2017-07-07 | 2024-09-09 | Takeda Pharmaceuticals Co | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää |
| EP3648787B1 (en) * | 2017-07-07 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf |
| AU2018321131B2 (en) * | 2017-08-23 | 2024-06-13 | Csl Behring Gmbh | Method for virus filtration of von Willebrand Factor |
| JP7763589B2 (ja) | 2018-05-18 | 2025-11-04 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病ａを処置する方法 |
| CA3123045A1 (en) * | 2018-12-23 | 2020-07-02 | Csl Behring L.L.C. | Donor t-cells with kill switch |
| JP2022524291A (ja) | 2019-02-01 | 2022-05-02 | 武田薬品工業株式会社 | 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法 |
| CN111592591B (zh) * | 2020-06-17 | 2021-12-14 | 博雅生物制药集团股份有限公司 | 一种人血管性血友病因子/人凝血因子ⅷ复合物的制备方法及产物和应用 |
| CN117720671B (zh) * | 2024-01-30 | 2024-06-14 | 南通大学 | 具有自组装性能的重复结构单元重组蛋白ⅠAⅠB-ⅠAⅠBrQTY及应用 |
| CN121319224A (zh) * | 2025-12-18 | 2026-01-13 | 山东艾科达生物科技有限公司 | 一种检测adamts13活性的蛋白组合及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| FR2673632A1 (fr) * | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5364771A (en) * | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| EP0793504B1 (en) | 1994-12-12 | 2005-06-08 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| US6103077A (en) * | 1998-01-02 | 2000-08-15 | De Nora S.P.A. | Structures and methods of manufacture for gas diffusion electrodes and electrode components |
| DE69922189T2 (de) | 1998-04-27 | 2005-11-10 | Opperbas Holding B.V. | Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2003530838A (ja) * | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| EP1148063A1 (de) | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
| EP1351986A2 (en) | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| JP2005535588A (ja) | 2002-04-29 | 2005-11-24 | バクスター・インターナショナル・インコーポレイテッド | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
| BR0317134A (pt) * | 2002-12-09 | 2005-11-22 | American Bioscience Inc | Composições e métodos de liberação de agentes farmacológicos |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| CA2788505C (en) | 2003-02-26 | 2018-09-04 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PT1624891E (pt) | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| EA008831B1 (ru) | 2003-06-12 | 2007-08-31 | Эли Лилли Энд Компани | Слитые белки аналогов glp-1 |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| WO2005024044A2 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| WO2005063808A1 (en) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US7632921B2 (en) | 2004-11-12 | 2009-12-15 | Bayer Healthcare Llc | Site-directed modification of FVIII |
| DK1835938T3 (da) * | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| US20110124565A1 (en) | 2005-04-14 | 2011-05-26 | Hans-Peter Hauser | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives |
| CN101351229A (zh) * | 2005-10-28 | 2009-01-21 | 生物载体株式会社 | 血液凝固异常的治疗方法 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| PL2032607T5 (pl) | 2006-06-14 | 2017-10-31 | Csl Behring Gmbh | Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi |
| DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| US9402754B2 (en) * | 2010-05-18 | 2016-08-02 | Abbott Cardiovascular Systems, Inc. | Expandable endoprostheses, systems, and methods for treating a bifurcated lumen |
| CN111499761A (zh) | 2012-01-12 | 2020-08-07 | 比奥贝拉蒂治疗公司 | 嵌合因子viii多肽及其用途 |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
-
2009
- 2009-06-24 DK DK14192277.3T patent/DK2865760T3/en active
- 2009-06-24 KR KR1020147018123A patent/KR101648734B1/ko not_active Expired - Fee Related
- 2009-06-24 CN CN201310596839.1A patent/CN103739712B/zh not_active Expired - Fee Related
- 2009-06-24 ES ES14192277.3T patent/ES2654336T3/es active Active
- 2009-06-24 EP EP14192277.3A patent/EP2865760B1/en not_active Not-in-force
- 2009-06-24 ES ES09768986.3T patent/ES2531464T3/es active Active
- 2009-06-24 EP EP09768986.3A patent/EP2291523B1/en active Active
- 2009-06-24 WO PCT/EP2009/004549 patent/WO2009156137A1/en not_active Ceased
- 2009-06-24 CN CN200980123818XA patent/CN102076855A/zh active Pending
- 2009-06-24 DK DK09768986T patent/DK2291523T3/en active
- 2009-06-24 JP JP2011515200A patent/JP5832285B2/ja not_active Expired - Fee Related
- 2009-06-24 RU RU2011102366/10A patent/RU2528855C2/ru active
- 2009-06-24 PL PL09768986T patent/PL2291523T3/pl unknown
- 2009-06-24 US US13/000,938 patent/US8575104B2/en not_active Expired - Fee Related
- 2009-06-24 CA CA2728012A patent/CA2728012C/en not_active Expired - Fee Related
- 2009-06-24 AU AU2009262476A patent/AU2009262476C1/en not_active Ceased
- 2009-06-24 KR KR1020117001530A patent/KR101507718B1/ko not_active Expired - Fee Related
-
2013
- 2013-09-17 US US14/028,869 patent/US9290561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525363A5 (enExample) | ||
| ES2685611T3 (es) | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo | |
| JP5902679B2 (ja) | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン | |
| RU2011102366A (ru) | Фактор viii, фактор виллебранда или их комплексы с удлиненным полупериодом существования in vivo | |
| ES2329334T3 (es) | Formas multimericas de ligandos de la superfamilia de tnf. | |
| WO2024109611A1 (zh) | 突变型呼吸道合胞病毒融合前f蛋白及其应用 | |
| JP5291671B2 (ja) | 融合タンパク質の免疫原性の低減 | |
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| JP2021003120A (ja) | 止血疾患を治療するための変異因子ｖｉｉｉのゲノム組込及び発現のための改良された発現カセット | |
| WO2010105573A1 (zh) | 抗血管新生融合蛋白 | |
| JP2015500811A5 (enExample) | ||
| JP2017529059A5 (enExample) | ||
| JP2013541335A5 (enExample) | ||
| CN104039833A (zh) | 针对hpv的疫苗 | |
| JP2018538003A5 (enExample) | ||
| JP2024180560A5 (enExample) | ||
| JP2017529326A5 (enExample) | ||
| CN103965362B (zh) | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 | |
| CA2261562A1 (en) | Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses | |
| WO2023030444A1 (zh) | Glp-1/gip双靶多肽、融合蛋白及其应用 | |
| CN109320615A (zh) | 靶向新型bcma的嵌合抗原受体及其用途 | |
| JP2022517267A (ja) | 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター | |
| JP2014517690A5 (enExample) | ||
| TWI250164B (en) | Highly purified cytokine activating factor and methods of use | |
| IL293822A (en) | Cd122 with altered icd stat signaling |